Treatment of Type II Inflammatory Disorders by Inhibiting Dkk-1 Activity

Description:

- Dr. Bothwell and his colleagues at Yale have discovered a novel role of Dkk-1 in type 2 immune responses.

- Upon environmental challenges, Dkk-1 is secreted from and circulated by platelets to facilitate leukocyte migration and polarize immune responses by inducing Th2 cell polarization.

- Functional inhibition of Dkk-1 protects mice from chronic type 2 inflammation in house dust mite (HDM)-induced asthma and Leishmania major cutaneous infection.

- Dkk-1 is an attractive target for controlling type 2 immune responses.

- **Intellectual property** – A patent application has been filed


**PI:** Alfred Bothwell

**Licensing Contact:** Hong Peng
hong.peng@yale.edu